RT Journal Article
T1 Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.
A1 Vallejo-Vaz, Antonio J
A1 Bray, Sarah
A1 Villa, Guillermo
A1 Brandts, Julia
A1 Kiru, Gaia
A1 Murphy, Jennifer
A1 Banach, Maciej
A1 De-Servi, Stefano
A1 Gaita, Dan
A1 Gouni-Berthold, Ioanna
A1 Kees-Hovingh, G
A1 Jozwiak, Jacek J
A1 Jukema, J Wouter
A1 Gabor-Kiss, Robert
A1 Kownator, Serge
A1 Iversen, Helle K
A1 Maher, Vincent
A1 Masana, Luis
A1 Parkhomenko, Alexander
A1 Peeters, Andre
A1 Clifford, Piers
A1 Raslova, Katarina
A1 Siostrzonek, Peter
A1 Romeo, Stefano
A1 Tousoulis, Dimitrios
A1 Vlachopoulos, Charalambos
A1 Vrablik, Michal
A1 Catapano, Alberico L
A1 Poulter, Neil R
A1 Ray, Kausik K
K1 Atherosclerotic cardiovascular disease
K1 Cardiovascular disease prevention
K1 Cardiovascular risk
K1 LDL-C
K1 Lipid-lowering
K1 Statins
AB PurposeLow-density lipoprotein cholesterol (LDL-C) recommendations differ between the 2018 American College of Cardiology / American Heart Association (ACC/AHA) and 2019 European Society of Cardiology /European Atherosclerosis Society (ESC/EAS) guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) (< 70 vs. < 55 mg/dl, respectively). In the DA VINCI study, residual cardiovascular risk was predicted in ASCVD patients . The extent to which relative and absolute risk might be lowered by achieving ACC/AHA versus ESC/EAS LDL-C recommended approaches was simulated.MethodsDA VINCI was a cross-sectional observational study of patients prescribed lipid -lowering therapy  (LLT) across 18 European countries. Ten-year cardiovascular risk (CVR) was predicted among ASCVD patients receiving stabilized LLT. For patients with LDL-C ≥ 70 mg/dl, the absolute LDL-C reduction required to achieve an LDL-C of < 70 or < 55 mg/dl (LDL-C of 69 or 54 mg/dl, respectively) was calculated. Relative and absolute risk reductions (RRRs and ARRs) were simulated.ResultsOf the 2039 patients , 61% did not achieve LDL-C < 70 mg/dl. For patients with LDL-C ≥ 70 mg/dl, median (interquartile range) baseline LDL-C and 10-year CVR were 93 (81–115) mg/dl and 32% (25–43%), respectively. Median LDL-C reductions of 24 (12–46) and 39 (27–91) mg/dl were needed to achieve an LDL-C of 69 and 54 mg/dl, respectively. Attaining ACC/AHA or ESC/EAS goals resulted in simulated RRRs of 14% (7–25%) and 22% (15–32%), respectively, and ARRs of 4% (2–7%) and 6% (4–9%), respectively. ConclusionIn ASCVD patients , achieving ESC/EAS LDL-C goals could result in a 2% additional ARR over 10 years versus the ACC/AHA approach
PB Springer New York LLC
YR 2023
FD 2023-10
LK http://hdl.handle.net/10668/20496
UL http://hdl.handle.net/10668/20496
LA en
NO Vallejo-Vaz AJ, Bray S, Villa G, Brandts J, Kiru G, Murphy J, et al. Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI. Cardiovasc Drugs Ther. 2023 Oct;37(5):941-953.
DS RISalud
RD Aug 16, 2025